Literature DB >> 30618075

MicroRNA-375-3p inhibitor suppresses angiotensin II-induced cardiomyocyte hypertrophy by promoting lactate dehydrogenase B expression.

Huijuan Feng1, Juqing Wu1, Pan Chen1, Jing Wang1, Yuying Deng1, Guoquan Zhu1, Jialang Xian1, Liuhua Huang1, Wei Ouyang1.   

Abstract

Cardiac hypertrophy is a myocardial enlargement due to overload pressure, and the primary cause of heart failure. We investigated the function of miR-375-3p in cardiac hypertrophy and its regulating mechanisms. miR-375-3p was upregulated in hearts of the transverse aortic constriction rat model and angiotensin II (Ang II)-induced primary cardiomyocyte hypertrophy model; the opposite was observed for lactate dehydrogenase B (LDHB) protein expression. miR-375-3p knockdown reduced the surface area of primary cardiomyocytes increased by Ang II treatment and decreased the B-natriuretic peptide (BNP) and β-myosin heavy chain (β-MHC) messenger RNA (mRNA) and protein levels. miR-375-3p was also observed to directly target LDHB. LDHB knockdown increased the surface area of Ang II-treated primary cardiomyocytes and increased the BNP and β-MHC mRNA and protein levels. LDHB knockdown attenuated the effects of miR-375-3p on the surface area of primary cardiomyocytes and BNP and β-MHC levels. Therefore, miR-375-3p inhibitor suppresses Ang II-induced cardiomyocyte hypertrophy by promoting LDHB expression.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  cardiac hypertrophy; lactate dehydrogenase B; miR-375-3p

Mesh:

Substances:

Year:  2019        PMID: 30618075     DOI: 10.1002/jcp.28116

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  6 in total

Review 1.  Left Ventricular Hypertrophy: Roles of Mitochondria CYP1B1 and Melatonergic Pathways in Co-Ordinating Wider Pathophysiology.

Authors:  George Anderson; Gianluigi Mazzoccoli
Journal:  Int J Mol Sci       Date:  2019-08-20       Impact factor: 5.923

2.  Amniotic Fluid microRNA in Severe Twin-Twin Transfusion Syndrome Cardiomyopathy-Identification of Differences and Predicting Demise.

Authors:  Eleanor L Schuchardt; Shelley D Miyamoto; Timothy Crombleholme; Anis Karimpour-Fard; Armin Korst; Bonnie Neltner; Lisa W Howley; Bettina Cuneo; Carmen C Sucharov
Journal:  J Cardiovasc Dev Dis       Date:  2022-01-23

3.  Oxytocin Protects Against Isoproterenol-Induced Cardiac Hypertrophy by Inhibiting PI3K/AKT Pathway via a lncRNA GAS5/miR-375-3p/KLF4-Dependent Mechanism.

Authors:  Yuqiao Yang; Zhuoran Wang; Mengran Yao; Wei Xiong; Jun Wang; Yu Fang; Wei Yang; Haixia Jiang; Ning Song; Lan Liu; Jinqiao Qian
Journal:  Front Pharmacol       Date:  2021-12-03       Impact factor: 5.810

4.  Mechanism of microRNA regulating the progress of atherosclerosis in apoE-deficient mice.

Authors:  Xiaoqian Lou; Dawei Wang; Zehui Gu; Tengteng Li; Liqun Ren
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

5.  The Effects of Inhibition of MicroRNA-375 in a Mouse Model of Doxorubicin-Induced Cardiac Toxicity.

Authors:  Hao Zhang; Yikui Tian; Degang Liang; Qiang Fu; Liqun Jia; Dawei Wu; Xinyuan Zhu
Journal:  Med Sci Monit       Date:  2020-03-18

Review 6.  MicroRNAs in Cardiac Hypertrophy.

Authors:  Nadine Wehbe; Suzanne Awani Nasser; Gianfranco Pintus; Adnan Badran; Ali H Eid; Elias Baydoun
Journal:  Int J Mol Sci       Date:  2019-09-23       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.